New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
05:29 EDTPLXProtalix announces first patient treated in Phase I/II study of Fabry patients
Protalix BioTherapeutics announced that the first patient has been treated in the company's phase I/II clinical trial of Fabry patients with PRX-102. PRX-102 is the company's proprietary plant cell-expressed, chemically modified recombinant alpha-galactosidase-A enzyme in development as a long-term enzyme replacement therapy for the treatment of Fabry disease.
News For PLX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 16, 2015
09:19 EDTPLXOn The Fly: Pre-market Movers
HIGHER: Nexvet Biopharma (NVET), up 16.8% after NV-01 study meets primary endpoint... Protalix BioTherapeutics (PLX), up 4.8% after announcing that it will conduct a Phase III clinical trial for PRX-102... Array Biopharma (ARRY), up 4.3% after announcing a commercialization collaboration with Pierre Fabre... Perrigo (PRGO), up 2.1% after being upgraded to Buy from Neutral at UBS. DOWN AFTER EARNINGS: Dillard's (DDS), down 11.7% after reporting quarterly results. ALSO LOWER: Clovis Oncology (CLVS), down 71.3% after the FDA requested additional clinical data for rociletinib... KaloBios Pharmaceuticals (KBIO), down 48.9% after announcing that it will wind down its operations... Starwood Hotels (HOT), down 6.3% after announcing that Marriott (MAR) will acquire the company... Marriott is down 2.4%... Five Below (FIVE), down 3.1% after being downgraded to Hold from Buy at Deutsche Bank.
07:06 EDTPLXProtalix to conduct Phase III clinical trial for PRX-102
Subscribe for More Information
November 13, 2015
16:08 EDTPLXProtalix files $100M mixed securities shelf
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use